UGT2B17 and B-cell chronic lymphocytic leukemia: We also evidenced that UGT2B17-dependent glucuronidation of prostaglandin E2 (PGE2) impairs anti-oncogenic PGE2 effects in leukaemic cells, thereby potentially contributing to disease progression in CLL patients with high levels of UGT2B17.52 Furthermore, given its predictive role in the drug response, as described above, UGT2B17 has a dual role in determining the fate of patients with CLL, given that it is linked to disease progression as well as drug resistance (discussed above).